Precipio to distribute HemeScreen® through Fisher Healthcare channel
July 20, 2022 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has entered into an agreement with Fisher Healthcare,...
Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote
June 14, 2022 14:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced today that the Company’s 2022 Annual Meeting of Stockholders was adjourned...
Keith Meadors Joins Precipio to Lead its Products Division
June 13, 2022 11:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., June 13, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that Keith Meadors has joined Precipio as its Senior Vice...
Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe
May 24, 2022 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that it has received CE-IVD approval for sale of its...
Precipio Signs First IV-Cell Customer Agreement
May 10, 2022 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that American Oncology Network (AON) of Fort Myers, Florida,...
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
April 26, 2022 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen,...
Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call
March 22, 2022 18:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 22, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2021 and year end shareholder update call on Monday,...
Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO
March 21, 2022 17:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that Mr. Carl Iberger, Precipio’s CFO for the past five...
Precipio Releases Year-End 2021 Preliminary Unaudited Results and Outlook for 2022
February 24, 2022 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced its unaudited and preliminary results for 2021. The Company...
New York State Approves Precipio’s HemeScreen for POL clinical use
November 18, 2021 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that its HemeScreen RUO assay has received the required approval from...